QIAGEN N.V.

QGEN · NYSE

QIAGEN generated about $2.09 billion of 2025 revenue, $466 million of operating income and $654 million of operating cash flow. The thesis depends on sample-to-insight diagnostics demand, consumables quality, regional exposure, capital discipline and debt-funded portfolio investment.

Follow Add to Watchlist Ask Question

NYSE QGEN Coverage Bootstrap QIAGEN N.V.

Latest ReportMay 20, 2026QIAGEN: a diagnostics platform where cash flow has to fund the next growth legView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

NYSECoverage Bootstrap

Clear tags

MatchAny tag All tags

Latest Thesis

QIAGEN: a diagnostics platform where cash flow has to fund the next growth leg

May 20, 2026Research reportSlides available

Read report Open slides Discussion (0)

QIAGEN N.V.a diagnostics platform where cash flow has to fund the next growMay 20, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

ReportTypeUpdatedReadActions

QIAGEN: a diagnostics platform where cash flow has to fund the next growth legQIAGEN generated about $2.09 billion of 2025 revenue, $466 million of operating income and $654 million of operating cash flow. The thesis depends on sample-to-insight diagnostics demand, consumables quality, regional exposure, capital discipline and debt-funded portfolio investment.NYSEMay 20, 2026Research reportRead Slides